Parameter | LX | TBP | P value |
---|---|---|---|
(N = 255) | (N = 299) | ||
Age (year) | |||
  < 50 | 137(53.7%) | 161(53.8%) | 0.977 |
  ≥ 50 | 59(23.1%) | 95(31.8%) | 0.024 |
 Unknown | 59(23.1%) | 43(14.4%) | 0.008 |
Menopausal status | |||
 Premenopausal | 40(15.7%) | 68(20.7%) | 0.126 |
 Postmenopausal | 182(71.4%) | 204(68.2%) | 0.422 |
 Unknown | 33(12.9%) | 27(9%) | 0.14 |
HR Status | |||
 Negative | 136(53.3%) | 145(48.5%) | 0.256 |
 Positive | 92(36.1%) | 139(46.5%) | 0.013 |
 Unknown | 27(10.6%) | 15(5%) | 0.014 |
 Stage IV at initial diagnosis | 32(12.5%) | 55(18.4%) | 0.059 |
Number of metastatic sites | |||
  < 3 | 178(69.8%) | 190(63.5%) | 0.12 |
  ≥ 3 | 77(30.2%) | 109(36.5%) |  |
Metastases | |||
 Lung | 123(48.2%) | 162(54.2%) | 0.163 |
 Liver | 109(42.7%) | 143(47.8%) | 0.213 |
 Bone | 62(24.3%) | 86(28.8%) | 0.238 |
 Brain | 24(9.4%) | 34(11.4%) | 0.453 |
 Other | 131(51.4%) | 150(50.2%) | 0.78 |
Resistance | |||
 Primary | 96(37.6%) | 109(38.1%) | 0.772 |
 Secondary | 159(62.4%) | 190(61.9%) |  |
Treatment line | |||
 1 | 37(14.5%) | 43(14.4%) | 0.966 |
 2 | 94(36.9%) | 164(54.8%) | <0.001 |
 3 | 124(48.6%) | 92(30.8%) | 0.001 |
Previous therapy | |||
 Hormonal | |||
  Adjuvant | 76(29.8%) | 96(32.1%) | 0.559 |
  Metastatic | 60(23.5%) | 91(30.4%) | 0.069 |
Radiotherapy | |||
 Adjuvant | 86(33.7%) | 104(34.8%) | 0.794 |
 Metastatic | 44(17.3%) | 54(18.1%) | 0.804 |
Previous trastuzumab failure | |||
 Adjuvant | 37(14.5%) | 43(14.4%) | 0.966 |
 Metastatic | 218(85.5%) | 256(85.6%) |  |
Previous trastuzumab treatment | |||
 Adjuvant | 78(30.6%) | 67(22.4%) | 0.029 |
 Advanced disease only | 177(69.4%) | 232(77.6%) |  |